

# Pocket Guide to Parenteral Nutrition

THIRD EDITION

**Dietitians in Nutrition Support  
Dietetic Practice Group**

EDITORS

**Emily Schwartz, DCN, RD, CNSC,**

**Renee Walker, MS, RD, LD, CNSC,**

**FAND, FASPEN**

**eat right.** Academy of Nutrition  
and Dietetics

ACADEMY OF NUTRITION AND DIETETICS  
CHICAGO, IL

Academy of Nutrition and Dietetics  
120 S. Riverside Plaza, Suite 2190  
Chicago, IL 60606

*Academy of Nutrition and Dietetics Pocket Guide to Parenteral Nutrition,*  
Third Edition

ISBN 978-0-88091-285-3 (print)  
ISBN 978-0-88091-286-0 (eBook)  
Catalog Number 369X26 (print)  
Catalog Number 369X26e (eBook)

Copyright © 2026, Academy of Nutrition and Dietetics. All rights reserved, including those for text and data mining, AI training, and similar technologies. Except for brief quotations embodied in critical articles or reviews, no part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written consent of the publisher.

The views expressed in this publication are those of the authors and do not necessarily reflect policies and/or official positions of the Academy of Nutrition and Dietetics. Mention of product names in this publication does not constitute endorsement by the authors or the Academy of Nutrition and Dietetics. Neither the Academy nor the authors or editors assume any liability for injury and/or damage to persons or property as a matter of liability, negligence, or otherwise from use of any methods, products, instructions, or applications of information contained herein.

10 9 8 7 6 5 4 3 2 1

For more information on the Academy of Nutrition and Dietetics, visit  
[www.eatright.org](http://www.eatright.org).

LCCN: 2025039429

# Contents

iv	<b>List of Boxes, Tables, and Figures</b>
vii	<b>Frequently Used Terms and Abbreviations</b>
ix	<b>Contributors</b>
x	<b>Reviewers</b>
xi	<b>Preface</b>
xii	<b>Acknowledgments</b>
1	<b>Chapter 1:</b> Assessment for Parenteral Nutrition in Adults
13	<b>Chapter 2:</b> Vascular Access Devices
31	<b>Chapter 3:</b> Parenteral Nutrients and Formulations
55	<b>Chapter 4:</b> Initiation, Advancement, and Acute Complications of Parenteral Nutrition
73	<b>Chapter 5:</b> Metabolic Complications of Long-Term Parenteral Nutrition
87	<b>Chapter 6:</b> Parenteral Nutrition in the Home and Alternate Sites
115	<b>Appendix:</b> Repletion Guidelines for Magnesium, Phosphorus, and Potassium
123	<b>Continuing Professional Education and Additional Notes</b>
124	<b>Index</b>

# List of Boxes, Tables, and Figures

- 3    **BOX 1.1** Nutrition Assessment Information  
Pertinent to Use of Parenteral Nutrition
- 6    **BOX 1.2** Examples of Conditions Likely  
to Require Parenteral Nutrition
- 8    **BOX 1.3** Clinical Conditions Warranting Cautious  
Initiation of Parenteral Nutrition in Adults
- 16    **BOX 2.1** Calculating the Osmolarity of  
Parenteral Nutrition Solutions
- 18    **BOX 2.2** Advantages and Disadvantages of Central Vascular  
Access Devices Used for Home Parenteral Nutrition
- 22    **BOX 2.3** Early Complications Associated  
With Central Catheter Placement
- 24    **BOX 2.4** Late, Noninfectious Complications  
Associated With Central Catheters
- 33    **BOX 3.1** Determination of Glucose Infusion  
Rate Based on Desired Dextrose Intake
- 36    **BOX 3.2** Daily Electrolyte Requirements  
for Adult Parenteral Nutrition
- 41    **BOX 3.3** Daily Vitamin Requirements  
for Adult Parenteral Nutrition
- 42    **BOX 3.4** Daily Trace Element Requirements  
for Adult Parenteral Nutrition
- 47    **BOX 3.5** Advantages and Disadvantages of 3-in-  
1 Solutions (Total Nutrient Admixtures)
- 49    **BOX 3.6** Examples of Parenteral Nutrition  
Formulation Prescription Calculations
- 50    **BOX 3.7** Advantages and Disadvantages of  
Multichamber Bag Parenteral Nutrition

- 59 **BOX 4.1** Factors to Consider When Advancing Parenteral Nutrition Volume and Macronutrients
- 62 **BOX 4.2** Insulin Therapy Options During Parenteral Nutrition
- 63 **BOX 4.3** Risk Factors for Hypertriglyceridemia
- 64 **BOX 4.4** Strategies to Limit or Avoid Complications Associated With Intravenous Lipid Emulsion
- 65 **BOX 4.5** Examples of Risk Factors for Refeeding Syndrome
- 66 **BOX 4.6** Strategies to Prevent and Treat Refeeding Syndrome
- 68 **BOX 4.7** Ways to Minimize the Effect of Parenteral Nutrition on Hepatic Function
- 74 **BOX 5.1** Potential Etiologies of Parenteral Nutrition–Associated Liver Disease
- 75 **BOX 5.2** Macronutrient Recommendations That May Reduce Risk of Parenteral Nutrition–Associated Liver Disease
- 76 **BOX 5.3** Micronutrients and Non-Nutrient Factors That Can Affect Risk of Developing Parenteral Nutrition–Associated Liver Disease
- 78 **BOX 5.4** Factors That Contribute to Metabolic Bone Disease
- 82 **BOX 5.5** General Dosage Recommendations for Specific Nutrients in Long-Term Parenteral Nutrition
- 84 **BOX 5.6** Suggestions for Reducing the Risk of Complications Associated With Long-Term Parenteral Nutrition
- 89 **BOX 6.1** Indications for Home Parenteral Nutrition
- 90 **BOX 6.2** Medical Contraindications to Home Initiation of Parenteral Nutrition
- 90 **BOX 6.3** Social Issues That Are Potential Contraindications to Home Parenteral Nutrition
- 92 **BOX 6.4** Medicare Reimbursement Criteria for Home Parenteral Nutrition
- 93 **BOX 6.5** Information Needed to Complete a Certificate of Medical Necessity for Home Parenteral Nutrition

- 97 **BOX 6.6** Home Infusion Pharmacy: Discharge Orders and Supply Information
- 101 **BOX 6.7** Self-Monitoring of Fluid Balance
- 104 **BOX 6.8** Signs and Symptoms of Metabolic Abnormalities
- 105 **BOX 6.9** Patient Guide to Managing Parenteral Nutrition Complications
- 108 **BOX 6.10** Laboratory Monitoring of Home Parenteral Nutrition
- 110 **BOX 6.11** Example of Routine Clinic Follow-Up Schedule
- 117 **BOX A1** Notes for Magnesium Repletion
- 119 **BOX A2** Notes for Phosphorus Repletion
- 121 **BOX A3** Notes for Potassium Repletion
- 35 **TABLE 3.1** Daily Doses of Different Intravenous Lipid Emulsion Formulas to Prevent Essential Fatty Acid Deficiency
- 57 **TABLE 4.1** Laboratory Monitoring During Parenteral Nutrition (Adult and Pediatric)
- 96 **TABLE 6.1** Treating Hyperglycemia and Hypoglycemia During Parenteral Nutrition Infusion
- 116 **TABLE A1** Repletion Guidelines for Hypomagnesemia
- 118 **TABLE A2** Repletion Guidelines for Hypophosphatemia
- 120 **TABLE A3** Repletion Guidelines for Hypokalemia
- 15 **FIGURE 2.1** Vascular access sites for parenteral nutrition
- 18 **FIGURE 2.2** Catheters for home parenteral nutrition
- 100 **FIGURE 6.1** Home parenteral nutrition teaching checklist
- 102 **FIGURE 6.2** Parenteral nutrition self-monitoring record

# Frequently Used Terms and Abbreviations

<b>AA</b>	amino acid
<b>AAA</b>	aromatic amino acid
<b>AAC</b>	acute acalculous cholecystitis
<b>ACD</b>	automated compounding device
<b>AMA</b>	American Medical Association
<b>ASHP</b>	American Society of Health-System Pharmacists
<b>ASPEN</b>	American Society for Parenteral and Enteral Nutrition
<b>BCAA</b>	branched chain amino acid
<b>CDC</b>	Centers for Disease Control and Prevention
<b>CII</b>	continuous insulin infusion
<b>CKD</b>	chronic kidney disease
<b>CMN</b>	certificate of medical necessity
<b>CRBSI</b>	catheter-related blood stream infection
<b>CT</b>	computed tomography
<b>CVAD</b>	central vascular access device
<b>DME</b>	durable medical equipment
<b>DXA</b>	dual energy x-ray absorptiometry
<b>EFAD</b>	essential fatty acid deficiency
<b>EN</b>	enteral nutrition
<b>FDA</b>	US Food and Drug Administration
<b>GIR</b>	glucose infusion rate
<b>HPN</b>	home parenteral nutrition

<b>IDPN</b>	interdialytic parenteral nutrition
<b>ILE</b>	intravenous lipid emulsion
<b>INR</b>	international normalized ratio
<b>LCD</b>	local coverage determination
<b>MBD</b>	metabolic bone disease
<b>MCB</b>	multichamber bag
<b>NCP</b>	Nutrition Care Process
<b>NFPE</b>	nutrition-focused physical examination
<b>NST</b>	nutrition support team
<b>PICC</b>	peripherally inserted central catheter
<b>PN</b>	parenteral nutrition
<b>PNALD</b>	parenteral nutrition–associated liver disease
<b>PPN</b>	peripheral parenteral nutrition
<b>QOL</b>	quality of life
<b>RDN</b>	registered dietitian nutritionist
<b>RN</b>	registered nurse
<b>SCCM</b>	Society of Critical Care Medicine
<b>SVC</b>	superior vena cava
<b>TNA</b>	total nutrient admixture
<b>USP</b>	United States Pharmacopeia
<b>VAD</b>	vascular access device



# Contributors

**Beth Peterson, MS, RD, CSO, LDN, CNSC**

Senior Clinical Dietitian,  
UMass Memorial Medical Center  
Worcester, MA

**Denise Jezerski, RD, LD, CNSC**

Home Nutrition Support Dietitian,  
Cleveland Clinic  
Cleveland, OH

**Emily Schwartz, DCN, RD, CNSC**

Clinical Dietitian Specialist,  
Touchpoint Support Services, Henry Ford Health  
Novi, MI

**Renee Walker, MS, RD, LD, CNSC, FAND, FASPEN**

Advanced Practice Dietitian,  
Michael E. DeBakey VA Medical Center  
Houston, TX

**Shelby Yaceczko, DCN, RDN-AP, CNSC, CCTD**

Advanced Practice Dietitian,  
UCLA Health  
Los Angeles, CA

# Reviewers

**Amber Ashcroft, BSN, RN**

Registered Nurse,  
Metabolic Support Services, Henry Ford Providence Southfield  
Southfield, MI

**Judy K. Brown, RDN, LD, CNSC**

Clinical Dietitian Specialist,  
Michael E. DeBakey VA Medical Center  
Houston, TX

**Nicolette Burzawa, RDN, LDN, CNSC**

Senior Nutrition Support Dietitian,  
Option Care Health  
Chicago, IL

**Roaxana Poskey, MS, RDN, LD, CNSC, FAND**

Dietitian, Advanced Level Practice–Nutrition Support,  
Michael E. DeBakey VA Medical Center  
Houston, TX

**Bridget Storm, MA, RD-AP, LDN, CNSC**

Clinical Dietitian,  
Metz Culinary Management  
Wilmington, DE

# Preface

Since the 1960s, parenteral nutrition (PN) has been used to provide IV nutrition support for individuals with altered gastrointestinal function. Due to the complexity of compounding PN and the numerous components involved, PN is considered a high-risk medication with potential for errors. It is crucial for practitioners involved in recommending, prescribing, and ordering PN to understand how to deliver appropriate and effective nutrition support to achieve optimal outcomes.

This is the third edition of the *Academy of Nutrition and Dietetics Pocket Guide to Parenteral Nutrition*. This guide explores who should start PN, appropriate vascular access devices, differences among PN nutrients and formulations, and the process of initiating and advancing a PN regimen. It also offers strategies for managing complications in both patients receiving acute PN or long-term PN. In addition, it provides guidance for patients receiving PN at home and in alternative care settings.

The tables and figures in this edition have been updated, simplified, and clarified to reflect current research, practice guidelines, and consensus recommendations. Additional updates include discussion of refeeding syndrome consensus statement recommendations, adjustments to account for additional IV lipid availability, updated Medicare criteria for PN, and specific guidance on electrolyte repletion.

We extend many thanks to our subject matter experts for the countless hours spent revising the pocket guide. We hope that you find this third edition of the *Academy of Nutrition and Dietetics Pocket Guide to Parenteral Nutrition* a beneficial and invaluable tool for your PN practice.

# Acknowledgments

We wish to thank the authors and reviewers for contributing their time and expertise to the third edition of the *Academy of Nutrition and Dietetics Pocket Guide to Parenteral Nutrition*. The field of nutrition is constantly evolving, and updating these pocket guides on an ongoing basis is crucial to ensure that practices remain evidence-based, effective, and aligned with the most current knowledge. We also wish to thank the Academy of Nutrition and Dietetics publications team for their guidance and support in bringing this publication to life. We thank the workgroups from previous editions of this pocket guide for their contributions and vision, particularly past editors Pamela Charney, PhD, RDN, LDN, FAND, and Ainsley Malone, MS, RDN, LD, CNSC, FAND, FASPEN. Finally, we would like to thank the Dietitians in Nutrition Support dietetic practice group for providing support and a group of clinicians with a priceless depth of knowledge.

This book is dedicated to our families, who make our lives fuller, louder, and infinitely more interesting; and to our patients, who are the driving force of our work and whose journeys continue to inspire us.

***Emily Schwartz, DCN, RD, CNSC, editor***

***Renee Walker, MS, RD, LD, CNSC, FAND, FASPEN, editor***

# 1

## Assessment for Parenteral Nutrition in Adults

*Beth Peterson, MS, RD, CSO, LDN, CNSC*

Patients who are not able to digest, absorb, or metabolize nutrients via the gastrointestinal (GI) tract may be candidates for parenteral nutrition (PN). PN provides nutrients via infusion into the venous system, thus bypassing the GI tract. PN is a life-sustaining modality but has potential for significant risks and complications. To promote patient safety and facilitate best outcomes, clinicians should understand and implement the recommendations for PN provided in best practice documents, clinical practice guidelines, and consensus statements, in addition to using well-developed clinical judgment.

### The Nutrition Care Process

The Nutrition Care Process (NCP) was developed by the Academy of Nutrition and Dietetics as a mechanism to provide nutrition and dietetics professionals with a framework for critical thinking and decision-making in all practice settings.<sup>1</sup> The 4 steps of the NCP, and how they relate to PN, are as follows<sup>2</sup>:

- **Nutrition assessment** of the patient receiving PN, which is covered in detail in this chapter.
- **Nutrition diagnosis**, which is a standardized approach to stating the nutrition-related problem, its etiology, and signs and symptoms. Common problem statements that may be associated with the need for PN include (but are not limited to) the following:
  - > inadequate energy intake
  - > inadequate oral intake
  - > inadequate enteral nutrition (EN) infusion
  - > inadequate protein-energy intake
  - > altered GI function
  - > impaired nutrient utilization
- **Nutrition interventions** directly related to PN, which may include:
  - > initiating PN;
  - > modifying the rate, concentration, composition, schedule, and duration of the feeding;
  - > providing PN site care;
  - > transitioning feeding modalities; or
  - > coordinating home PN care.
- **Nutrition monitoring and evaluation** of PN, which generally encompasses adequacy of nutrient provision, anthropometrics, laboratory measurements, and other relevant clinical parameters. This step is covered in detail in Chapters 4 and 5.

## Assessment

When determining whether PN is appropriate, the clinician should first complete a comprehensive nutrition assessment and formulate a diagnosis of nutrition problems that preclude oral or enteral feeding. A comprehensive assessment includes evaluation of the patient's clinical status, the functional capacity of the GI tract, and the ability to access the GI tract. Information gathered from a thorough review of the patient's clinical condition (eg, renal function, hydration, glucose tolerance, or electrolyte homeostasis) and medical history (eg, history of congestive heart failure, diabetes, or pulmonary dysfunction) guides the development of a

comprehensive nutrition care plan. Confirmation of seriously altered or absent GI tract function may be obtained from intake and output reports, results of an EN trial, radiology (eg, CT scan or x-ray) or surgery reports, and GI studies (eg, endoscopy).

Per the NCP, information from 5 categories gathered during the nutrition assessment can be used to diagnose nutrition problems and guide selection of the appropriate nutrition interventions. Box 1.1 provides examples of findings from the nutrition assessment that may be associated with appropriate selection of PN as a nutrition intervention.<sup>2</sup>

<b>BOX 1.1 Nutrition Assessment Information Pertinent to Use of Parenteral Nutrition<sup>2</sup></b>	
<b>Category</b>	<b>Findings pertinent to parenteral nutrition</b>
Anthropometric measurements	<ul style="list-style-type: none"> <li>▪ Weight loss</li> <li>▪ Poor weight gain</li> </ul>
Food-/nutrition-related history	<ul style="list-style-type: none"> <li>▪ Inability to tolerate oral or enteral nutrition despite adjustments to diet or enteral formula</li> </ul>
Biochemical data, medical tests, and procedures	<ul style="list-style-type: none"> <li>▪ Endoscopy results</li> <li>▪ Diagnostic imaging (CT, MRI, or ultrasound)</li> <li>▪ Surgical reports</li> </ul>
Physical examination findings	<ul style="list-style-type: none"> <li>▪ Subcutaneous fat loss</li> <li>▪ Muscle wasting</li> <li>▪ Presence of edema</li> </ul>
Client history	<ul style="list-style-type: none"> <li>▪ Significant history of gastrointestinal disorders</li> </ul>

## Patient Selection and Consideration of Risks

Appropriate patient selection for PN is critical, as PN carries higher risks of adverse effects compared to oral feeding or EN.<sup>3</sup> Before deciding to initiate PN, the clinician must carefully evaluate the patient's nutrition needs and clinical status and determine whether EN alone is appropriate.

### EXPERT INSIGHT

*Ordering, compounding, administering, and evaluating PN is a complex, high-risk procedure; therefore, it is vital that all clinicians who are caring for patients receiving PN demonstrate competency.<sup>4,5</sup>*

Worthington et al<sup>6</sup> noted that the broad variety of health care settings in which PN is used, along with the decline in the number of dedicated nutrition support teams, “raises the potential for gaps to exist in the expertise of clinicians initiating and managing PN therapy.”

Considering its inherent risks and cost, PN should not be used as a substitute for EN if either standard care (defined as “little or no nutrition intervention,” ie, oral diet as tolerated with IV hydration) or EN is feasible.<sup>3</sup> In a meta-analysis published in 2001, EN and standard care were generally associated with a lower risk of infection compared with PN.<sup>3</sup> More recently, several randomized clinical trials have evaluated the effectiveness of EN vs PN in adult patients who are critically ill; researchers concluded that there is no significant difference in mortality risk associated with the use of parenteral or enteral routes of administration in these patients.<sup>7,8</sup> However, evidence continues to support the use of early EN when feasible to reduce infectious and other clinical complications associated with complete bowel rest.<sup>9</sup>

### EXPERT INSIGHT

*If EN alone is not feasible, the clinician must determine whether PN (alone or in a supplemental role) is appropriate to fully meet nutrition needs, as well as to ideally maintain or improve nutritional status. Identifying appropriate patient populations and optimizing glucose control, central venous catheter care, and macronutrient and micronutrient intake may positively affect the response to PN.<sup>10,11</sup>*



## Appropriate Use of Parenteral Nutrition

In 2014, the Board of Directors of the American Society for Parenteral and Enteral Nutrition (ASPEN) convened an interprofessional task force to review questions surrounding PN use. According to the report generated by the task force, the group decided against an article that “narrowly focused on *indications* for PN” in favor of a document that guides the reader to the “*appropriate use* of PN therapy in a variety of clinical circumstances.” This document reflects consensus recommendations, largely due to the lack of published research of sufficient quality to create evidence-based guidelines. The recommendations are intended to help clinicians identify best practices, guide decisions (if possible), eliminate variations in practice, and, above all, improve patient safety.<sup>6</sup>

Although PN is a life-sustaining medical intervention for some patients, the task force recommended that PN should not be prescribed solely based on a specific medical diagnosis, clinical condition, or disease state, as PN has not been shown to be an effective treatment modality except in the case of malnutrition.<sup>6</sup> Clinical practice guidelines and consensus recommendations suggest that PN be used in patients who are<sup>6,12,13</sup>:

- already malnourished or at high risk for becoming malnourished;
- not candidates for EN;
- unable to meet their needs with EN alone;
- without sufficient bowel length and/or function to maintain or restore nutritional status; or
- likely to need PN therapy for weeks, months, or years.

Box 1.2 on page 6 provides examples of conditions likely to require PN.<sup>6</sup>

**BOX 1.2** Examples of Conditions Likely to Require Parenteral Nutrition<sup>6</sup>

Category	Example	Clinical features
Impaired absorption or loss of nutrients	Short bowel syndrome (both mechanical and functional), complications of bariatric surgery, volvulus, mesenteric thrombosis, or trauma	Bowel length (adults): 60 cm with the colon in continuity, 120 cm without the colon in continuity Weight loss, failure to thrive, or fluid and electrolyte disturbances
	High-output intestinal fistula (more than 500 mL/d)	Bypasses a significant absorptive mucosal area; location precludes enteral access or results in high-volume output with enteral nutrition (EN)
	Neutropenic colitis	Opportunistic infection in an immunocompromised patient
Mechanical bowel obstruction	Small bowel mucosal disease: <ul style="list-style-type: none"> <li>■ Radiation- or chemotherapy-related enteritis</li> <li>■ Congenital diseases (microvillus inclusion disease, or tufting enteropathy)</li> <li>■ Autoimmune enteropathy</li> </ul>	Intractable diarrhea, weight loss, failure to thrive, or unresponsive to medical management
	Intrinsic or extrinsic blockage of the intestinal lumen: <ul style="list-style-type: none"> <li>■ Stenosis or strictures</li> <li>■ Inflammatory disease</li> <li>■ Peritoneal carcinomatosis</li> <li>■ Severe adhesive disease</li> <li>■ Severe superior mesenteric artery syndrome</li> </ul>	Recurrent or intractable vomiting, or limited oral intake Unamenable to medical, surgical, or interventional treatment (placement of stent or enteral access device)

Need to restrict oral or enteral intake: bowel rest	Ischemic bowel	Mesenteric artery stenosis, intestinal angina, abdominal compartment syndrome, or low flow states
	Severe pancreatitis	Increased pain or serum lipase levels with EN, infected pancreatic phlegmon or pseudocyst, complex pancreatic fistula, or abdominal compartment syndrome
	Chylous fistula	Increased output with low-fat diet or elemental formula
Motility disorders	Perioperative status	Severely malnourished adults with a nonfunctional gastrointestinal tract for 7 to 10 days prior to surgery
	Prolonged ileus	Diffuse peritonitis related to medical treatment or other disease state Time to intervention varies per nutrition and clinical status
	Pseudo-obstruction, scleroderma, visceral organ myopathy, or very long—segment Hirschsprung disease	Failure to tolerate adequate oral intake or EN
	Severe adhesive disease	“Frozen abdomen” <sup>a</sup> with chronic obstructive symptoms and malnutrition
	Varies with clinical circumstances	Hemodynamic instability, active gastrointestinal bleeding, severe neutropenic fever, or inability to place tube due to mechanical reasons
Inability to achieve or maintain enteral access		

<sup>a</sup> A condition in which the abdominal organs and compartmental structures lose their natural space, causing tissues to stick together with loss of functionality. Often characterized by abdominal pain, infection, and impaired intestinal transit.

Adapted with permission from Worthington P, Balint J, Bechtold M, et al. When is parenteral nutrition appropriate? *JPEN J Parenter Enteral Nutr.* 2017;41(3):324-377. doi:10.1177/0148607117695251<sup>6</sup>

## Timing of Parenteral Nutrition

Evidence-based recommendations suggest the following guidance regarding the timing of PN initiation<sup>6,13,14</sup>:

- Initiate PN after 7 days in adult patients who are stable and well-nourished, and who have been unable to receive significant ( $\geq 50\%$  of estimated requirements) oral or enteral nutrients.
- Initiate PN within 3 to 5 days in those who are nutritionally at risk and unlikely to achieve desired oral intake or EN, including patients who are critically ill.
- Initiate PN as soon as feasible for patients with baseline moderate or severe malnutrition when oral intake or EN is not possible or sufficient.
- Delay initiation in a patient with severe metabolic instability until the patient's condition has improved. Refer to Box 1.3.<sup>6,14</sup>

### BOX 1.3 Clinical Conditions Warranting Cautious Initiation of Parenteral Nutrition in Adults<sup>6,14</sup>

Condition	Suggested criterion
Hyperglycemia	Glucose greater than 300 mg/dL
Azotemia	Blood urea nitrogen greater than 100 mg/dL
Hypernatremia	Serum sodium greater than 150 mEq/L
Hypokalemia	Serum potassium less than 3 mEq/L
Hypomagnesemia	Serum magnesium less than 1.3 mg/dL
Hypophosphatemia	Serum phosphorus less than 2 mg/dL

## Recommendations for Supplemental Parenteral Nutrition

Clinical practice guidelines recommend considering supplemental PN if enteral or oral feedings are unable to meet at least 60% of the patient's calorie and protein requirements for 7 to 10 days, whether the patient is at high or low nutrition risk.<sup>13</sup> Guidelines published in 2022 recommend against using supplemental PN prior to day 7 of intensive care unit admission.<sup>15</sup>

However, when used as the primary feeding modality, either EN or PN is acceptable in the first week of critical illness.<sup>14,15</sup>

## Use of Peripheral Parenteral Nutrition

The ASPEN task force developed the following consensus recommendations regarding the use of peripheral PN (PPN)<sup>6</sup>:

- Use PPN only for short-term purposes (no more than 10 to 14 days), as supplemental PN or as a bridge therapy during transition periods, or when a central venous catheter cannot be placed.
- Maintain an upper limit of 900 mOsm/L for PPN formulations.

Contraindications for use of PPN include significant malnutrition, severe metabolic stress (eg, hypercatabolism), large nutrient or electrolyte needs, fluid restriction, need for prolonged PN (>2 weeks), and renal or liver compromise.<sup>14</sup>

## Other Clinical Situations for Parenteral Nutrition Use

Appropriate PN use has also been evaluated in specific clinical situations. Consensus recommendations, as well as other considerations, follow.

### *Intradialytic Parenteral Nutrition*

Intradialytic PN (IDPN) should not be used as the primary nutrition intervention in patients who are malnourished and have chronic kidney disease (CKD).<sup>6</sup> Because IDPN typically only provides 500 to 1,000 kcal per dialysis treatment and intermittent dialysis treatments are provided 2 to 3 times per week for most patients, IDPN can only play a supplemental role for patients with CKD who are malnourished and unable to tolerate adequate oral or enteral intake. Existing data suggest IDPN is safe for selected patients, but the risks, complications, and financial costs have not been thoroughly studied.<sup>6,16</sup>

### *Perioperative Parenteral Nutrition*

EN is generally preferred in the preoperative period, but preoperative PN may be considered for patients who are severely malnourished and unable to tolerate adequate oral intake or EN.<sup>6</sup> Postoperatively, PN may be appropriate for patients who are severely malnourished and unable to tolerate EN for more than 7 days.<sup>6</sup>

## *Palliative Care*

PN should not be used solely to treat poor oral intake or cachexia associated with advanced malignancy. Clinicians must consider the risk-to-benefit ratio when evaluating the use of PN in palliative care.<sup>6</sup> Recommendations state to “limit the use of PN in palliative care to carefully selected candidates, with an expected survival of at least 2 to 3 months, for whom oral intake or EN is not feasible and for whom quality of life and the potential burden of long-term PN has been assessed and discussed.”<sup>6,17</sup> A time-limited trial of PN may be appropriate for patients whose prognosis is uncertain or whose nutritional decline may be reversible.

## *Home Parenteral Nutrition*

Common indications for home PN (HPN) include the following<sup>6</sup>:

- short bowel syndrome
- Crohn’s disease
- intestinal motility disorders
- chronic bowel obstruction due to benign adhesions or strictures
- radiation enteritis
- malabsorptive disorders
- intestinal and pancreatic fistula
- GI malignancy
- malignant bowel obstruction (carcinomatosis)
- complications of bariatric surgery
- gastroschisis
- long-segment Hirschsprung disease

HPN may be considered for patients who have GI failure (as demonstrated by one of the aforementioned indications), are clinically stable, and can safely receive therapy outside of an acute care setting. Clinicians must thoroughly evaluate medical and psychosocial factors that influence suitability for HPN, as well as address financial considerations and patient responsibilities with the patient and the caregiver.<sup>6</sup> Refer to Chapter 6 for more information on HPN.

## Contraindications for Enteral Nutrition: Indications for Parenteral Nutrition?

Some relative or absolute contraindications to feeding tube placement may require initiation of PN.<sup>6</sup> The clinician should carefully evaluate each patient individually.

- Overall contraindications to obtaining EN access that may necessitate PN initiation include mechanical obstruction of the GI tract, uncontrolled peritonitis, uncorrected coagulopathy or thrombocytopenia, GI bleeding, or bowel ischemia.
- Contraindications for nasal feeding tube placement may include basilar skull fracture; recent transsphenoidal surgery; facial, sinus, or nasal trauma; or significant esophageal disease (including recent variceal banding).
- Contraindications for abdominal feeding tube placement may include massive ascites, hemodynamic instability, morbid obesity, or short duration of use (<4 weeks).

## References

1. Commission on Dietetic Registration. Nutrition Care Process and Terminology. Accessed August 3, 2024. [www.cdrnet.org/nutrition-care-process-and-terminology](http://www.cdrnet.org/nutrition-care-process-and-terminology)
2. Academy of Nutrition and Dietetics. Electronic Nutrition Care Process Terminology. 2023. Accessed December 9, 2024. [www.ncpro.org/pubs/2023-encpt-en](http://www.ncpro.org/pubs/2023-encpt-en)
3. Braunschweig CL, Levy P, Sheean PM, Wang X. Enteral compared with parenteral nutrition: a meta-analysis. *Am J Clin Nutr*. 2001;74(4):534-542. doi:10.1093/ajcn/74.4.534
4. Corrigan ML, Bobo E, Rollins C, Mogensen KM. Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: revised 2021 standards of practice and standards of professional performance for registered dietitian nutritionists (competent, proficient, and expert) in nutrition support. *Nutr Clin Pract*. 2021;36(6):1126-1143. doi:10.1002/ncp.10774
5. National Board of Nutrition Support Certification, Inc. Candidate Handbook. 2025. Accessed March 5, 2025. <https://nutritioncare.org/nbnsc/wp-content/uploads/sites/9/2025/02/NBNSC-Candidate-Handbook-2025.pdf>
6. Worthington P, Balint J, Bechtold M, et al. When is parenteral nutrition appropriate? *JPEN J Parenter Enteral Nutr*. 2017;41(3):324-377. doi:10.1177/0148607117695251
7. Harvey SE, Parrott F, Harrison DA, et al. Trial of the route of early nutritional support in critically ill adults. *N Engl J Med*. 2014;371(18):1673-1684. doi:10.1056/NEJMoa1409860
8. Reignier J, Boisramé-Helms J, Brisard L, et al. Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2). *Lancet*. 2018;391(10116):133-143. doi:10.1016/S0140-6736(17)32146-3
9. Talebi S, Zeraattalab-Motlagh S, Vajdi M, et al. Early vs delayed enteral nutrition or parenteral nutrition in hospitalized patients: an umbrella review of systematic reviews and meta-analyses of randomized trials. *Nutr Clin Pract*. 2023;38(3):564-579. doi:10.1002/ncp.10976

10. Sacks GS. Enhancing the response to parenteral nutrition in critical care. *Nutr Clin Pract.* 2004;19(3):226-234. doi:10.1177/0115426504019003226
11. McCleary EJ, Tajchman S. Parenteral nutrition and infection risk in the intensive care unit: a practical guide for the bedside clinician. *Nutr Clin Pract.* 2016;31(4):476-489. doi:10.1177/0884533616653808
12. Tappenden KA, Quatrara B, Parkhurst ML, Malone AM, Fanjiang G, Ziegler TR. Critical role of nutrition in improving quality of care: an interdisciplinary call to action to address adult hospital malnutrition. *JPEN J Parenter Enteral Nutr.* 2013;37(4):482-497. doi:10.1177/0148607113484066
13. McClave SA, Taylor BE, Martindale RG, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). *JPEN J Parenter Enteral Nutr.* 2016;40(2):159-211. doi:10.1177/0148607115621863
14. Mirtallo J, Mulherin DW. Overview of parenteral nutrition. In: Chan LN, ed. *The ASPEN Adult Nutrition Support Core Curriculum*. 4th ed. American Society for Parenteral and Enteral Nutrition; 2025:387-402.
15. Compher C, Bingham AL, McCall M, et al. Guidelines for the provision of nutrition support therapy in the adult critically ill patient: the American Society for Parenteral and Enteral Nutrition. *JPEN J Parenter Enteral Nutr.* 2022;46(1):12-41. doi:10.1002/jpen.2267
16. Dukkupati R, Kalantar-Zadeh K, Kopple JD. Is there a role for intradialytic parenteral nutrition? A review of the literature. *Am J Kidney Dis.* 2010;55(2):352-364. doi:10.1053/j.ajkd.2009.08.006
17. Cotogni P, Stragliotto S, Ossola M, et al; on behalf of the Intersociety Italian Working Group for Nutritional Support in Cancer. The role of nutritional support for cancer patients in palliative care. *Nutrients.* 2021;22;13(2):306. doi:10.3390/nu13020306